[go: up one dir, main page]

WO2008129624A1 - ピラゾロピリジン－４－イルピラゾロン誘導体とその付加塩及びそれを有効成分とするホスホジエステラーゼ阻害剤 - Google Patents

ピラゾロピリジン－４－イルピラゾロン誘導体とその付加塩及びそれを有効成分とするホスホジエステラーゼ阻害剤 Download PDF

Info

Publication number
WO2008129624A1
WO2008129624A1 PCT/JP2007/057905 JP2007057905W WO2008129624A1 WO 2008129624 A1 WO2008129624 A1 WO 2008129624A1 JP 2007057905 W JP2007057905 W JP 2007057905W WO 2008129624 A1 WO2008129624 A1 WO 2008129624A1
Authority
WO
WIPO (PCT)
Prior art keywords
pyrazolopyridine
active ingredient
same
addition salt
pyrazolone derivative
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2007/057905
Other languages
English (en)
French (fr)
Inventor
Yasushi Kohno
Naoki Ando
Koji Ochiai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kyorin Pharmaceutical Co Ltd
Original Assignee
Kyorin Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Pharmaceutical Co Ltd filed Critical Kyorin Pharmaceutical Co Ltd
Priority to PCT/JP2007/057905 priority Critical patent/WO2008129624A1/ja
Publication of WO2008129624A1 publication Critical patent/WO2008129624A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

　下記一般式（１） で表される新規なピラゾロピリジン－４－イルピラゾロン誘導体（具体例：６－（２－エチル－７－メトキシ－ピラゾロ[１，５－ａ]ピリジン－４－イル）－４，４－ジメチル－２，４－ジヒドロ－３－ピラゾロン）は、ホスホジエステラーゼ阻害作用を有する医薬品として有用である。
PCT/JP2007/057905 2007-04-10 2007-04-10 ピラゾロピリジン－４－イルピラゾロン誘導体とその付加塩及びそれを有効成分とするホスホジエステラーゼ阻害剤 Ceased WO2008129624A1 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/JP2007/057905 WO2008129624A1 (ja) 2007-04-10 2007-04-10 ピラゾロピリジン－４－イルピラゾロン誘導体とその付加塩及びそれを有効成分とするホスホジエステラーゼ阻害剤

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2007/057905 WO2008129624A1 (ja) 2007-04-10 2007-04-10 ピラゾロピリジン－４－イルピラゾロン誘導体とその付加塩及びそれを有効成分とするホスホジエステラーゼ阻害剤

Publications (1)

Publication Number Publication Date
WO2008129624A1 true WO2008129624A1 (ja) 2008-10-30

Family

ID=39875172

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2007/057905 Ceased WO2008129624A1 (ja) 2007-04-10 2007-04-10 ピラゾロピリジン－４－イルピラゾロン誘導体とその付加塩及びそれを有効成分とするホスホジエステラーゼ阻害剤

Country Status (1)

Country Link
WO (1) WO2008129624A1 (ja)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014448A1 (en) * 1996-10-04 1998-04-09 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridylpyridazinone derivatives and process for the preparation thereof
JP2006117647A (ja) * 2004-09-22 2006-05-11 Kyorin Pharmaceut Co Ltd ハロゲノピラゾロピリジンピリダジノン誘導体とその付加塩及びそれを有効成分とするｐｄｅ阻害剤
JP2006169138A (ja) * 2004-12-14 2006-06-29 Kyorin Pharmaceut Co Ltd ピラゾロピリジンピラゾロン誘導体とその付加塩及びｐｄｅ阻害剤
WO2006095666A1 (ja) * 2005-03-07 2006-09-14 Kyorin Pharmaceutical Co., Ltd. ピラゾロピリジン－４－イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤
JP2007091597A (ja) * 2005-09-27 2007-04-12 Kyorin Pharmaceut Co Ltd ピラゾロピリジン−４−イルピラゾロン誘導体とその付加塩及びそれを有効成分とするホスホジエステラーゼ阻害剤

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998014448A1 (en) * 1996-10-04 1998-04-09 Kyorin Pharmaceutical Co., Ltd. Pyrazolopyridylpyridazinone derivatives and process for the preparation thereof
JP2006117647A (ja) * 2004-09-22 2006-05-11 Kyorin Pharmaceut Co Ltd ハロゲノピラゾロピリジンピリダジノン誘導体とその付加塩及びそれを有効成分とするｐｄｅ阻害剤
JP2006169138A (ja) * 2004-12-14 2006-06-29 Kyorin Pharmaceut Co Ltd ピラゾロピリジンピラゾロン誘導体とその付加塩及びｐｄｅ阻害剤
WO2006095666A1 (ja) * 2005-03-07 2006-09-14 Kyorin Pharmaceutical Co., Ltd. ピラゾロピリジン－４－イルピリダジノン誘導体とその付加塩及びそれらを有効成分とするｐｄｅ阻害剤
JP2007091597A (ja) * 2005-09-27 2007-04-12 Kyorin Pharmaceut Co Ltd ピラゾロピリジン−４−イルピラゾロン誘導体とその付加塩及びそれを有効成分とするホスホジエステラーゼ阻害剤

Similar Documents

Publication Publication Date Title
WO2008156094A1 (ja) ピリダジノン誘導体及びそれらを有効成分とするｐｄｅ阻害剤
WO2007090141A3 (en) Pyrrolo [2, 3, b] pyridine derivatives useful as raf kinase inhibitors
WO2008120725A1 (ja) 新規ピロリノン誘導体およびそれを含有する医薬組成物
WO2009060835A8 (ja) 新規ユビキリン結合性小分子
WO2007023382A3 (en) Pyrimidine amino pyrazole compounds, potent kinase inhibitors
TN2011000245A1 (en) Organic compounds
EP2078721A3 (en) Thieno-pyrimidime compounds having fungicidal activity
WO2009016460A3 (en) Pyrazole compounds and their use as raf inhibitors
UA83091C2 (en) Pyrido[2,3-d]pyrimidine-2,4-diamines as pde 2 inhibitors
WO2007143705A3 (en) Organic compounds
WO2009007751A3 (en) Trisubstituted pyrimidine derivatives for the treatment of proliferative diseases
WO2006021454A3 (en) Pyrimidine derivatives
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
WO2007065664A3 (en) Pyrazolo[1,5-a]pyridine-3-carboxylic acids as ephb and vegfr2 kinase inhibitors
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2008067119A3 (en) Novel compounds
WO2006023515A3 (en) Novel thiazole inhibitors of fructose 1,6-bisphosphatase
EP1864665A4 (en) IMMUNOSUPPRESSIVE AGENT AND ANTI-TUMOR AGENT COMPRISING A HETEROCYCLIC COMPOUND AS ACTIVE INGREDIENT
WO2007146124A3 (en) Deuterated tadalafil derivatives
BRPI0514925A (pt) derivados de pirrol[2,3-c]piridina e processos para a preparação destes
WO2006021457A3 (en) Pyrimidine derivatives
PL2170068T3 (pl) Sposób zwalczania owadów
WO2008093838A1 (ja) スルファモイル基を有するピリジルイミダゾリジン誘導体、およびその医薬としての使用
EP1477490A4 (en) PYRROLOPYRIMIDINE DERIVATIVE
WO2007099171A3 (en) Bicyclo-pyrazoles active as kinase inhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07741341

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07741341

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP